Insights

Treasury Wine Estates (TWE)

Pre-COVID, TWE was one of the ASX’s great growth stocks, delivering shareholders strong returns over many years. In recent years, COVID and the China tariffs on Australian imported wine have knocked the stock for six.

Just when its share price was starting to recover given Australia/China’s improving government relationship and the possibility that the absorbent tariffs could be removed, it announced a big acquisition of Paso Robles luxury wine business, DAOU Vineyards (DAOU) for US$900m (A$1.4bn). While the acquisition is in line with TWE’s premiumisation and growth strategy and will strengthen a key gap in Treasury Americas portfolio, it was much larger than the market was expecting.

Consequently, it required a large equity raising to fund it. It will therefore take some time for this raising to be absorbed by the market. Additionally, there have also been mixed views from some camps on the acquisition given TWE’s chequered history in the US under previous management teams. We take some comfort that its last acquisition in the US, Frank Family Vineyards, has gone extremely, well beating its original business case, albeit it was a much smaller acquisition than DAOU.

Post this transaction, TWE will become the largest player in the US luxury wine market. In the future, TWE will have two luxury wine businesses of scale – Penfolds and Treasury Americas Luxury. Both these businesses which are high margin and high growth, will make up the bulk of TWE’s earnings and will command higher trading multiples. Over time, to focus on its luxury wine businesses and to realise shareholder value, TWE may look to demerge or divest its much smaller Treasury Premium Brands business unit. The key near-term catalyst for the stock is China removing the tariffs on Australian wine imports.

TWE’s FY24 guidance and long-term earnings expectations do not assume any benefits from a positive outcome in relation to the review of tariffs on Australian wine into China. If China tariffs are removed, there is upside to its growth expectations over the coming years. While TWE will report a weak 1H24 result, from the 2H24 onwards it has the drivers in place to deliver solid earnings growth over the next few years. We are therefore taking advantage of recent share price weakness to get set for what should hopefully be a strong rerating over coming years.

Lovisa (LOV)

Although the share price of Lovisa has increased nearly 10x since listing at $2 nine years ago, the ride has never been a smooth one. Before the most recent correction, there have been three periods when the shares have fallen by more than 40% (June 2018 to January 2019; October 2019 to March 2020; and November 2021-June 2022) and, on each occasion, the price has bounced back to a new all-time high.

We’re confident the ~30% fall in the share price since April this year will be no different. To appreciate the reasons for our view, it’s important to understand the causes of this most recent period of share price weakness. One is the broader cyclical move away from consumer discretionary stocks due to concerns about household spending in the context of rising borrowing rates and stubbornly high inflation around the world.

Cycles turn, and when interest rates finally show signs of plateauing and inflation begins to normalise, it is likely investor sentiment towards the sector will warm up and Lovisa shares will be much sought-after as a way of playing the recovery.

A second reason for Lovisa’s recent share price underperformance is the recent move into negative like-for-like sales growth. So far this financial year, sales on a comparable store basis have fallen by 6%. Investors don’t like to see this, but it has been experienced against an unusually strong period last year when like-for-like growth was +16% following an uplift in selling prices. On a two-year basis, growth is still very positive. We expect negative like-for-like sales to be a temporary function of cycling strong comparative numbers and we expect a return to positive growth from around March next year.

Furthermore, the key value driver for Lovisa is the expansion of its global network and we think it should be remembered that Lovisa grew total sales by 17% in the first 20 weeks of FY24, demonstrating the benefit of this expansion. Lovisa recently announced that it will shortly be opening its first stores in mainland China (population: 1.4 billion) and Vietnam (population: 99 million), a development that could lock in substantial network expansion for the future.

Lovisa has proven it can successfully build out its unique brand in many diverse territories around the world on its journey to becoming a truly global brand. It’s at times like these that investors should be getting set to reap the rewards of this strategy over the longer term.

ResMed (RMD)

RMD has lost nearly A$7bn in market capitalisation (more than 1/3 of its total value) in a mere quarter, unprecedented in 24 years of listing, due to investor angst around the potential impact of weight loss drugs, namely GLP-1s (Glucagon-Like Peptide-1), in curtailing the core obstructive sleep apnoea (OSA) addressable market. Hype and hope tend to spring eternal in medicine.

We believe talk of an emerging weight loss drug ‘revolution’ should not feared as an existential threat, but instead as a unique opportunity to buy a quality global franchise at a discounted price, especially considering the impact of weight loss drugs is likely to be fairly limited given the following.

First, it is a mere fallacy to simply assume drugs that reduce obesity will ‘cure’ OSA, despite the majority (~65%) of OSA being linked to excess body weight. Unfortunately, nothing in medicine is ever that simple, especially when you are dealing with a complex, chronic disease that is driven by a myriad of underlying factors. Even bariatric surgery, which is and is likely to remain the most effective intervention for obesity treatment and long-term maintenance of body weight, is not a ‘cure’ for OSA. However, bariatric surgery has been shown to reduce OSA severity, but this has had no discernible impact on RMD’s top-line growth.

Second, weight loss drugs have historically suffered from low adherence and high relapse rates, along with a long and chequered safety profile. We have no reason to believe the latest iteration in this class, which is actually more than 15 years old, should not follow suit.

Third, affordability and accessibility should not be underestimated, as the prevalence of obesity is most acute in lower socio-economic demographics. Recent published reports indicate that ~25% of Americans already have difficulty affording their medications, with ~30% not taking their medicines as prescribed at some point in the past year due to the cost. At an annual cost of US$10-15k, GLP-1s are beyond the realms of affordability for most of the population.

Lastly, OSA represents a large (>1bn) and underdiagnosed (<5%) market for RMD’s gold standard continuous positive airway pressure (CPAP) devices. Even if we assume an aggressive 50% uptake of weight loss drugs, the OSA market for CPAP would remain deeply underserved (<10%). As such, it is really OSA diagnosis and not the potential competitive treatment from weight loss drugs, that is the limiting factor for the uptake of CPAP. More realistically, the weight loss drugs are likely to complement rather than compete with CPAP; ultimately, helping to increase awareness about obesity and opening up the market to more patients who seek treatment.

The bottom line, and in the words of ‘The Oracle of Omaha', “be fearful when others are greedy and be greedy only when others are fearful."

Morgans clients receive exclusive insights such as access to the latest stock and sector coverage featured in the Month Ahead. Contact us today to begin your journey with Morgans.

Morgans Chief Economist Michael Knox discusses the key drivers for the lack of a US recession in 2023 and explains why Joe Biden's economic policy isn't more popular.

Watch

Listen

Medibank (ASX:MPL) recently held its Annual General Meeting (AGM), where it reaffirmed key guidance metrics for the fiscal year 2024. Additionally, the Australian Prudential Regulation Authority (APRA) has released industry statistics for the Private Health Insurance (PHI) sector for the September quarter. In this analysis, we'll delve into these updates and provide insights into their implications for Medibank and the broader industry.

Medibank AGM Highlights

At the AGM, Medibank reiterated its guidance metrics for the fiscal year 2024, signalling confidence in its performance and outlook. This reaffirmation provides stakeholders with clarity and reassurance regarding the company's trajectory.

APRA's PHI Industry Statistics

APRA's release of industry statistics for the PHI sector offers valuable insights into market dynamics. Notably, the statistics indicate continued reasonable growth in industry policyholders, albeit with rising hospital treatment benefit growth, suggesting evolving trends within the sector.

Forecast Adjustments

Following a review of our earnings assumptions, we have made nominal changes to our Medibank EPS forecasts, reflecting adjustments of approximately 2%. Despite these adjustments, our price target remains largely unchanged.

Analysis

While the current operating environment appears relatively favourable for Medibank, with continued growth in policyholders and reasonable industry dynamics, we maintain a cautious stance. Trading at 18x FY24F PE, we view Medibank as fair value. Therefore, we maintain our HOLD recommendation on the stock.

In conclusion, the updates from Medibank's AGM and APRA's industry statistics offer valuable insights into the company's performance and broader market trends. As always, investors should conduct thorough research and consider their investment goals before making any decisions.

<<Insert button>>

Webjet (ASX:WEB) recently reported a robust 1H24 result that surpassed expectations. In this analysis, we delve into the highlights of the report, including the exceptional performance of WebBeds, industry-leading margins, and strong operating cash flow.

Performance Highlights

The standout performer in the 1H24 result was WebBeds, which achieved record bookings, surpassing pre-COVID levels by 50%. Additionally, the company showcased industry-leading margins and demonstrated strong operating cash flow, indicating a healthy financial position.

Outlook Commentary

While the outlook commentary was upbeat, recent geopolitical events have impacted bookings over the last six weeks. Despite this, FY24 EBITDA guidance aligns with our forecasts. However, if the impact from the ongoing events is short-lived, it could potentially prove conservative.

Investment Insights

With significant market share still up for grabs, we maintain an Add rating on Webjet, considering it a high-quality growth stock. Based on our forecasts, WEB is currently trading at a FY25F PE of 15.8x, which is notably lower than its five-year average PE (pre-COVID) of 20.6x.

Technology One (ASX:TNE) recently announced its latest financial results, which surpassed expectations, with revenue momentum standing out as a highlight. Notably, management has advanced their target of achieving $500 million in Annual Recurring Revenue (ARR) to FY25, bringing it forward from the previously projected FY26. This represents a significant acceleration in the company's growth trajectory.

Revenue Momentum

The strong performance in revenue underscores Technology One's resilience and ability to capitalize on market opportunities. The company's ability to exceed expectations bodes well for its future prospects and reinforces investor confidence.

Forecast Analysis

While the financial results were slightly better than anticipated, we have made marginal adjustments to our forecasts. Despite the positive momentum, we maintain our Hold recommendation on the stock.

Technology One's decision to advance its ARR target demonstrates its confidence in its business model and growth strategy. The company's ability to adapt and innovate positions it as a leader in the technology sector. Investors should closely monitor Technology One's performance as it continues to supercharge its ARR and pursue its ambitious targets.

Become a Morgans client to gain access to detailed market analysis and insights, provided by our award-winning research team.

Brickworks (ASX:BKW) recently provided a trading update ahead of its Annual General Meeting (AGM) today. The update revealed positive Q1FY24 Building Product EBIT results compared to the prior corresponding period (pcp). However, management expressed concerns regarding a softening outlook and announced plans to undertake maintenance work to manage stock levels. Additionally, the company anticipates a decline of approximately 10% in property net asset values for the first half of FY24, attributed to an increase in capitalization rates.

Trading Update Highlights

Brickworks' trading update presents a mixed picture, with positive EBIT results tempered by concerns about future prospects. Management's cautious commentary, particularly regarding the property segment, suggests potential challenges ahead.

Outlook and Analysis

The outlook commentary from Brickworks appears to be among the weakest within the building product peer group. Lower earnings are anticipated over the next 12 to 24 months, with the forecasted property cap rate change likely reflecting a catch-up with current market pricing trends.

Investment Insights

Despite Brickworks' share price trading at a discount to the inferred Net Asset Value (NAV), concerns about earnings headwinds relative to consensus forecasts lead us to maintain a Hold recommendation. We would consider upgrading our stance to Add if the share price were to approach $20/sh. However, our preferred exposure in the building products sector currently lies with CSR.

Brickworks faces short-term headwinds amid a challenging operating environment, particularly in the property segment. While the company's long-term value proposition remains intact, investors should exercise caution given the uncertainties in the near term.

Become a Morgans client to gain access to detailed market analysis and insights, provided by our award-winning research team.